Brentuximab Vedotin Plus Chemotherapy in Patients with Advanced-Stage Classical Hodgkin Lymphoma (cHL): Evaluation of Modified Progression-Free Survival (mPFS) and Traditional PFS in the Phase 3 ECHELON-1 Study
Joseph M. Connors, John Radford(Manchester Academic Health Science Centre), Rachael Liu(Takeda (United States)), Monika Długosz‐Danecka(National Institute of Oncology), Keenan Fenton(The Christie NHS Foundation Trust), Stephen M. Ansell(Mayo Clinic), Ranjana H. Advani(Stanford Medicine), Gerald Engley(Seagen (United States)), Martin Hutchings(University of Copenhagen), Anas Younes(Intercept Pharmaceuticals (United States)), Anna Sureda(Institut d'Investigació Biomédica de Bellvitge), Nancy L. Bartlett(Washington University in St. Louis), Hina Jolin(Takeda (United States)), Ashish Gautam(Moffitt Cancer Center), Won-Seog Kim(Samsung Medical Center), David J. Straus(Memorial Sloan Kettering Cancer Center), Harry Miao(Takeda (United States)), Andrea Gallamini(Centre Antoine Lacassagne)
Cited by 6
Related Papers
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
|New England Journal of Medicine|2002|3.9k
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Stromal Gene Signatures in Large-B-Cell Lymphomas
|New England Journal of Medicine|2008|1.8k